Skip to main content
Expand main menu
Close main menu
FDA OKs Kevzara
Kevzara is the first and only biologic indicated for patients with polymyalgia rheumatica.
RxBenefits unveils Patient Assistance program to lower cost of specialty drugs
The Patient Assistance solutions ensure patients receive their medications, even if alternative funding is unavailable or they don’t qualify for need-based assistance.
IQVIA reports global market for medicines to rise to $1.9 trillion by 2027
The underlying growth rate will be driven by new drug launches and wider use of recently launched brands.
Sun Pharma gains FDA OK for Sezaby
Sezaby is the first and only product approved for treating seizures in neonatal patients.
McKesson intros Atlas Specialty
Atlas Specialty builds upon the strength and expertise of Health Mart Atlas to bridge the gap between payers and providers.
Amber Specialty Pharmacy, WeInfuse’s Specialty Pharmacy Connect Program join forces
The partnership and integration will provide infusion centers with direct ordering access of specialty prescription medications.
Walmart broadens commitment to accelerate end of AIDS in the United States
Walmart's new HIV-focused efforts are aimed at eliminating AIDS in the United States.
AllianceRx Walgreens Pharmacy launches corporate giving program
St. Jude Children’s Research Hospital was chosen as the first recipient of proceeds from the AllianceCares' program’s semi-annual giving campaign.
Eugia Pharma Specialities gets FDA OK for generic AmBisome Liposome for Injection
Amphotericin B liposome for injection, 50 mg /vial is a partnership product from TTY Biopharm.
Sun Pharma, SPARC ink deal for commercialization of phenobarbital for injection
The product, which is awaiting FDA approval, is targeted at treating seizures in neonatal patients.
AllianceRx Walgreens Pharmacy reduces annual patient prescription costs by $6M
Clinical audit programs prevent waste, improve adherence, reduce spend and provide outcomes data, the company said.
Hikma, Glenmark Specialty launch Ryaltris
Ryaltris is used for the treatment of symptoms of seasonal allergic rhinitis in adult and pediatric patients 12 years of age and older.
Endo files for Chapter 11 bankruptcy
Endo and certain of its subsidiaries initiated voluntary prearranged Chapter 11 proceedings in New York.
Upsher-Smith, Emphascience ink deal for specialty branded generic product
Emphascience will develop the product exclusively for Upsher-Smith, which will manufacture, market and distribute it under its own label in the United States.